The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase III trial of the impact of a structured exercise program on disease-free survival (DFS) in stage 3 or high-risk stage 2 colon cancer: Canadian Cancer Trials Group (CCTG) CO.21 (CHALLENGE).
 
Christopher Booth
No Relationships to Disclose
 
Janette Vardy
No Relationships to Disclose
 
Christopher O'Callaghan
No Relationships to Disclose
 
Sharlene Gill
Honoraria - Amgen; Eisai
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb Canada; Eisai; Ipsen; Merck; Pfizer; Roche Canada
Research Funding - Incyte (Inst)
 
Christine Friedenreich
No Relationships to Disclose
 
Rebecca Wong
Honoraria - Elekta (Inst); Novartis
Research Funding - Bruce Power (Inst); Celgene/Bristol-Myers Squibb (Inst); POINT Biopharma (Inst); Precirix (Inst)
 
Haryana Dhillon
No Relationships to Disclose
 
Vicky Coyle
Honoraria - Gilead Sciences (I)
Consulting or Advisory Role - Merck
Speakers' Bureau - SERVIER
Research Funding - Astex Pharmaceuticals (Inst); Bayer (Inst); CellCentric (Inst)
Travel, Accommodations, Expenses - SERVIER
 
Neil Chua
Honoraria - Abbvie
Consulting or Advisory Role - Amgen; Bayer; Incyte; Merck; Roche Canada; Seagen
Research Funding - Roche/Genentech (Inst)
 
Derek Jonker
Research Funding - Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); BioNTech (Inst); Bold Therapeutics (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); HotSpot Therapeutics (Inst); Janssen (Inst); Merck (Inst); Mirati Therapeutics (Inst); Ocellaris Pharma (Inst); Pfizer (Inst); Qu Biologics (Inst); RGenta Therapeutics (Inst); RGenta Therapeutics (Inst); SeaGen (Inst)
 
Philip Beale
No Relationships to Disclose
 
Kamal Haider
Consulting or Advisory Role - Pfizer
 
Patricia Tang
Consulting or Advisory Role - AstraZeneca; Merck; Novartis Canada Pharmaceuticals Inc; Taiho Pharmaceutical
Speakers' Bureau - Apobiologix
Travel, Accommodations, Expenses - Amgen
 
Tony Bonaventura
No Relationships to Disclose
 
Ralph Wong
No Relationships to Disclose
 
Howard Lim
Honoraria - Amgen; Astellas Pharma; AstraZeneca Canada; BeiGene; BMS Canada; Dicephera Pharmaceuticals, Inc.; eisai; Ipsen; Merck; Roche Canada; Taiho Pharmaceutical; Takeda; Varian Medical Systems
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - Eisai; Taiho Oncology
 
Matthew Burge
Stock and Other Ownership Interests - coclear; CSL Limited; Lilly; pfizer
Honoraria - AstraZeneca; Bristol Myers squibb; Merck Sharp & Dohme; SERVIER
Consulting or Advisory Role - AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb/Medarex; merck srpe Dohme; SERVIER
Speakers' Bureau - Merck Sharpe Dohme
Research Funding - Amgen (Inst)
Patents, Royalties, Other Intellectual Property - funding for an investigator initiated prospective trial (Inst)
 
Patti O'Brien
No Relationships to Disclose
 
Dongsheng Tu
No Relationships to Disclose
 
Kerry Courneya
No Relationships to Disclose